The evolution of personalized cancer genetic counseling in the era of personalized medicine

Familial Cancer

Volumn 11, Issue 3, 2012, Pages 539-544

  Vig, Hetal S ^a   Wang, Catharine ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Cancer genetics; Genetic counseling models; Personalized medicine; Treatment based genetic counseling

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; BILATERAL MASTECTOMY; BREAST CANCER; CANCER GENETICS; CANCER SCREENING; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MASTECTOMY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENETIC COUNSELING; HETEROZYGOTE; HUMANS; INDIVIDUALIZED MEDICINE; MICROSATELLITE INSTABILITY;

EID: 84870424007     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9524-8     Document Type: Article

References (52)

1. Berliner JL, Fay AM (2007) Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 16(3):241-260
2. Trepanier AM (2008) 2007 National Society of Genetic Counselors presidential address: embracing change to race forward. J Genet Couns 17(1):2-5
3. Cavalli P (2009) Genetic counseling: a medical approach. Genet Test
4. Wham D, Vu T, Chan-Smutko G, Kobelka C, Urbauer D, Heald B (2010) Assessment of clinical practices among cancer genetic counselors. Fam Cancer 9(3):459-468
5. Balint J, Shelton W (1996) Regaining the initiative. Forging a new model of the patient-physician relationship. JAMA 275(11): 887-891
6. Laine C, Davidoff F (1996) Patient-centered medicine. A professional evolution. JAMA 275(2):152-156
7. Altman RB (2009) Direct-to-consumer genetic testing: failure is not an option. Clin Pharmacol Ther 86(1):15-17
8. Plon SE, Cooper HP, Parks B et al (2011) Genetic testing and cancer risk management recommendations by physicians for atrisk relatives. Genet Med 13(2):148-154
9. Peshkin BN, Demarco TA, Graves KD et al (2008) Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test 12(1):37-52
10. Abrams DJ, Geier MR (2006) A comparison of patient satisfaction with telehealth and on-site consultations: a pilot study for prenatal genetic counseling. J Genet Couns 15(3):199-205
11. Helmes AW, Culver JO, Bowen DJ (2006) Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns 64(1-3):96-103
12. Sutphen R, Davila B, Shappell H et al (2010) Real world experience with cancer genetic counseling via telephone. Fam Cancer 9(4):681-689
13. Mackay J, Taylor A (2006) Moving genetics into clinical cancer care: examples from BRCA gene testing and telemedicine. Breast 15(Suppl 2):S65-S70
14. Meropol NJ, Daly MB, Vig HS et al (2011) Delivery of Internetbased cancer genetic counselling services to patients' homes: a feasibility study. J Telemed Telecare 17(1):36-40
15. Gray J, Brain K, Iredale R, Alderman J, France E, Hughes H (2000) A pilot study of telegenetics. J Telemed Telecare 6(4):245-247
16. Coelho JJ, Arnold A, Nayler J, Tischkowitz M, MacKay J (2005) An assessment of the efficacy of cancer genetic counselling using real-time videoconferencing technology (telemedicine) compared to face-to-face consultations. Eur J Cancer 41(15):2257-2261
17. Zon RT, Goss E, Vogel VG et al (2009) American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 27(6): 986-993
18. Evans JP, Dale DC, Fomous C (2010) Preparing for a consumerdriven genomic age. N Engl J Med 363(12):1099-1103
19. Meiser B, Tucker K, Friedlander M et al (2008) Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res 10(6):216
20. Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823-1829
21. Patenaude AF, Orozco S, Li X et al (2008) Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psychooncology 17(8):831-843
22. Julian-Reynier C, Bouhnik AD, Mouret-Fourme E et al (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med 12(12): 801-807
23. Silva E (2008) Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist. Fam Cancer 7(1):91-95
24. Silva E, Lynch H (2006) Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations. Breast J 12(3):280-281 (author reply 2-4)
25. Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW (2004) Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Breast J 10(6):475-80
26. American Society of Clinical Oncology policy statement update (2003) Genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397-2406
27. ACOG Practice Bulletin No (2009) 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957-966
28. Wevers MR, Ausems MG, Verhoef S et al (2011) Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer 11:6
29. O'Connor AM, Stacey D, Rovner D et al (2001) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 3:CD001431
30. Lobb EA, Butow PN, Moore A et al (2006) Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study. J Genet Couns 15(5):393-405
31. Wakefield CE, Meiser B, Homewood J et al (2008) A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology 17(8):844-854
32. Culver JO, Macdonald DJ, Thornton AA et al (2011) Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns 20(3):294-307
33. Amir E, Seruga B, Serrano R, Ocana A (2010) Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev 36(7):557-565
34. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921
35. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3): 167-181
36. Bast RC Jr, Mills GB (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28(22):3545-3548
37. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134
38. O'Shaughnessy J. SL, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer (TNBC). American Society of Clinical Oncology annual meeting, Chicago, IL
39. Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5): 1082-1089
40. Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86
41. Hampel H, Frankel W, Panescu J et al (2006) Screening for lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810-7817
42. Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783-5788
43. Hampel H, Frankel WL, Martin E et al (2005) Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851-1860
44. Recommendations from the EGAPP Working Group (2009) Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from lynch syndrome in relatives. Genet Med 11(1):35-41
45. South CD, Yearsley M, Martin E, Arnold M, Frankel W, Hampel H (2009) Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med 11(11):812-817
46. de la Chapelle A, Hampel H (2004) Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28(20):3380-3387
47. Manne SL, Meropol NJ, Weinberg DS et al (2010) Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol 28(8):1366-1372
48. Acheson LS, Stange KC, Zyzanski S (2005) Clinical genetics issues encountered by family physicians. Genet Med 7(7): 501-508
49. Friedman LC, Cooper HP, Webb JA, Weinberg AD, Plon SE (2003) Primary care physicians' attitudes and practices regarding cancer genetics: a comparison of 2001 with 1996 survey results. J Cancer Educ 18(2):91-4
50. Wideroff L, Freedman AN, Olson L et al (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 12(4):295-303
51. Cohen SA, McIlvried D, Schnieders J (2009) A collaborative approach to genetic testing: a community hospital's experience. J Genet Couns 18(6):530-533
52. Vig HS, Armstrong J, Egleston BL et al (2009) Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 13(6):735-741